Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.
about
The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospectsWaldenström's macroglobulinemia: a clinical perspective in the era of novel therapeuticsNovel agents and biomarkers for acute lymphoid leukemiaAntibody Therapies in Cancer.Immunotherapy in pediatric malignancies: current status and future perspectivesTreatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma - novel and emerging therapies.Immunotherapy treatments of warm autoimmune hemolytic anemia.Novel monoclonal antibodies for therapy of multiple sclerosis.Biosimilar monoclonal antibodies in lymphoma: a critical appraisal.The human counterpart of mouse B-1 cells.Novel drug therapies in myeloid leukemia.Pharmacotherapeutic Management of Chronic Lymphocytic Leukaemia in Patients with Comorbidities: New Agents, New Hope.Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents.Obinutuzumab for the treatment of indolent lymphomaCurrent treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.Current options to manage Waldenström's macroglobulinemia.Real-time Characterization of Antibody Binding to Receptors on Living Immune Cells.Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.S2k Guidelines - Cutaneous Lymphomas Update 2016 - Part 2: Treatment and Follow-up (ICD10 C82 - C86).S2k-Leitlinie - Kutane Lymphome Update 2016 - Teil 2: Therapie und Nachsorge (ICD10 C82 - C86).[Treatment of indolent cutaneous B‑cell lymphoma].Cutaneous B-cell lymphomas - pathogenesis, diagnostic workup, and therapy.Ofatumumab (Arzerra®): a Next-Generation Human Therapeutic CD20 Antibody with Potent Complement-Dependent CytotoxicityPhase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenström’s macroglobulinemia
P2860
Q26770815-8693674E-4F08-4747-8B4D-FEAC01847118Q26776391-EDFC303B-7399-4B86-8059-F3E9AFF81DACQ26829775-1323C4F0-0862-4A9F-AF02-1531CBE33F09Q31104000-BE34C49E-E6F2-46B2-AAAD-51680788B649Q36691818-DB70EDB5-62C2-4504-A267-E99FA50BA8F0Q37178611-6A2542F5-1738-47C0-B624-A89D759DA8DDQ38150845-CF1722CB-F09F-45FE-9004-E84097BF0E05Q38191996-16900903-2D57-4B83-983F-A4F15997AA0AQ38394272-DEBD2D76-7F6B-4317-8D25-AE829E9117D9Q38491162-EDB3B630-4EE8-412B-9687-6BBB68980DBEQ38510486-F3B3F924-8E93-495F-A12B-94FA53B7B9C7Q38601727-A7CBFA9D-09A0-4673-A0CE-8D33852B1849Q38747100-18571159-6BEC-4709-9541-789562A41F9CQ38818380-0622C267-6EE0-4333-956D-C8A813C447C6Q39044362-D290302B-3E2A-4962-9458-B9703F6CCA55Q39188128-7D016BE2-E8C7-4E7A-9863-3C2F4815782DQ39358109-FA04EF34-E0A1-4EFB-8BAE-EDE933847F2EQ42290751-572ACBF7-0229-482D-9853-B1627375FE5DQ49539698-A89C22B0-A03B-46BB-BB71-121BAF297FB8Q49561302-38772571-1C8A-450A-9EA9-57FCDC4E4EDDQ50122599-FB26CE7A-8FDD-4C19-A98B-C8506D54AC7AQ53130617-20A0A222-0530-4ED9-B087-6B654B4411BBQ54205796-7EEB704E-6B9C-40E0-B0F3-423B33DA69CAQ56908538-AE77C387-68B6-4AE7-9EC0-DD617D3BBBE2Q57904151-6559588C-F9ED-4D94-A828-FDD63DAD57DB
P2860
Ofatumumab, the first human anti-CD20 monoclonal antibody for the treatment of B cell hematologic malignancies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Ofatumumab, the first human an ...... cell hematologic malignancies.
@en
type
label
Ofatumumab, the first human an ...... cell hematologic malignancies.
@en
prefLabel
Ofatumumab, the first human an ...... cell hematologic malignancies.
@en
P2860
P1476
Ofatumumab, the first human an ...... cell hematologic malignancies.
@en
P2093
Ira V Gupta
Roxanne C Jewell
P2860
P356
10.1111/J.1749-6632.2012.06661.X
P407
P577
2012-07-25T00:00:00Z